These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38822845)

  • 1. Effective management of heparin-resistant thrombosis: a case study on rivaroxaban therapy guided by thromboelastography.
    Hou C; Zhai B; Yang B; Zhang L; Li Y; Lu X
    Ann Hematol; 2024 Aug; 103(8):3267-3268. PubMed ID: 38822845
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Zarei B; Moghtadaei M; Nasiripour S; Ansarinejad N; Zarei M
    J Clin Pharmacol; 2020 Oct; 60(10):1362-1366. PubMed ID: 32519800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban in treatment refractory heparin-induced thrombocytopenia.
    Casan JM; Grigoriadis G; Chan N; Chunilal S
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27520997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for cancer-associated cardiac thrombosis.
    Di Nisio M; Carella C; Natoli C; Porreca E; De Tursi M
    Am J Med; 2015 Oct; 128(10):e43-4. PubMed ID: 26071831
    [No Abstract]   [Full Text] [Related]  

  • 5. The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients.
    Lv S; Liu Y; Wei G; Shi X; Chen S; Zhang X
    Medicine (Baltimore); 2019 Nov; 98(47):e17894. PubMed ID: 31764785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report].
    Rivera O G; Corsi S O; Pavlovic J A; Aizman S A; Varas A P
    Rev Med Chil; 2017 Sep; 145(9):1213-1217. PubMed ID: 29424412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
    Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
    Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
    Sugie M; Iizuka N; Shimizu Y; Ichikawa H
    Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
    Arachchillage DR; Besser M; Maclean R; Baglin T; van Veen JJ
    Thromb Res; 2016 Jul; 143():137-40. PubMed ID: 27244105
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanical Valve Thrombosis on Rivaroxaban: Are Novel Anticoagulants Really an Option?
    Kumar V; Kelly S; Raizada A; Yee J; Anuwatworn A; Stys A; Stys M
    Methodist Debakey Cardiovasc J; 2017; 13(2):73-75. PubMed ID: 28740586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical Prosthetic Heart Valve Thrombosis in a Patient Receiving Rivaroxaban.
    Carvalho Silva DM; Braga A; de Jesus I; Neves J
    Cardiology; 2019; 143(3-4):116-120. PubMed ID: 31473736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial.
    Vranckx P; Leebeek FW; Tijssen JG; Koolen J; Stammen F; Herman JP; de Winter RJ; van T Hof AW; Backx B; Lindeboom W; Kim SY; Kirsch B; van Eickels M; Misselwitz F; Verheugt FW
    Thromb Haemost; 2015 Aug; 114(2):258-67. PubMed ID: 25925992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
    Macedo KA; Tatarian P; Eugenio KR
    Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
    Bajko Z; Maier S; Motataianu A; Filep RC; Stoian A; Andone S; Balasa R
    Acta Neurol Belg; 2022 Feb; 122(1):105-111. PubMed ID: 33733345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence.
    Ong SY; Chin YA; Than H; Tan CW; Yap ES; Wong WH; Ng HJ
    Ann Hematol; 2017 Mar; 96(3):525-527. PubMed ID: 27822611
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of direct oral anticoagulants in patients with left ventricular thrombus.
    Chen K; Yu S; Zhu W; Liu X
    Eur J Intern Med; 2024 Aug; 126():132-133. PubMed ID: 38679498
    [No Abstract]   [Full Text] [Related]  

  • 17. The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis.
    Mohamed MFH; ElShafei MN; Ahmed MB; Abdalla LO; Ahmed I; Elzouki AN; Danjuma MI
    Clin Appl Thromb Hemost; 2021; 27():1076029620940046. PubMed ID: 33651658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report.
    Abouchakra L; Khabbaz Z; Abouassi S; Badaoui G
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):e19-20. PubMed ID: 26055438
    [No Abstract]   [Full Text] [Related]  

  • 20. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
    Guan Z; Wang R; Hussain RH; Fredenburgh JC; Jaffer IH; Weitz JI
    J Thromb Haemost; 2023 Jan; 21(1):76-82. PubMed ID: 36695399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.